Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy

2022 ◽  
Vol 74 ◽  
pp. 76-84
Author(s):  
Nils Wellhausen ◽  
Sangya Agarwal ◽  
Philipp C Rommel ◽  
Saar I Gill ◽  
Carl H June
2020 ◽  
Vol 20 ◽  
Author(s):  
Suman K Ray ◽  
Yamini Meshram ◽  
Sukhes Mukherjee

: Cancer immunotherapy endeavours in harnessing delicate strength and specificity of immune system for therapy of different malignancies including colorectal carcinoma. The recent challenge for cancer immunotherapy is to practice and develop molecular immunology tools to create tactics that efficiently and securely boost antitumor reactions. After several attempts of deceptive outcomes, the wave has lastly altered and immunotherapy has become a clinically confirmed treatment for several cancers. Immunotherapeutic methods include administration of antibodies or modified proteins that either block cellular activity or co-stimulate cells through immune control pathways, cancer vaccines, oncolytic bacteria, ex vivo activated adoptive transfer of T cells and natural killer cells. Engineered T cells are used to produce a chimeric antigen receptor (CAR) to treat different malignancies including colorectal carcinoma in a recent decade. Despite considerable early clinical success, CAR-T therapies are associated with some side effects and sometimes display minimal efficacy. It gives special emphasis on the latest clinical evidence with CAR-T technology and also other related immunotherapeutic methods with promising performance, and highlighted how this therapy can affect therapeutic outcome and next upsurge as a key clinical aspect of colorectal carcinoma. In this review we recapitulate the current developments produced to improve the efficacy and specificity of CAR-T therapies in colon cancer.


2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 3022-3022
Author(s):  
Michel Sadelain ◽  
Maud Condomines ◽  
Zeguo Zhao ◽  
Renier J. Brentjens ◽  
Isabelle Riviere

2020 ◽  
Vol 32 (5) ◽  
pp. 398-407
Author(s):  
Silvia Arcangeli ◽  
Katrin Mestermann ◽  
Justus Weber ◽  
Chiara Bonini ◽  
Monica Casucci ◽  
...  

2018 ◽  
Vol 24 (1) ◽  
pp. 78-83 ◽  
Author(s):  
Yan-Bei Ren ◽  
Shang-Jun Sun ◽  
Shuang-Yin Han

T-cell therapy using genetically engineered T cells modified with either T cell receptor or chimeric antigen receptor holds great promise for cancer immunotherapy. The concerns about its toxicities still remain despite recent successes in clinical trials. Temporal and spatial control of the engineered therapeutic T cells may improve the safety profile of these treatment regimens. To achieve these goals, numerous approaches have been tested and utilized including the incorporation of a suicide gene, the switch-mediated activation, the combinatorial antigen recognition, etc. This review will summarize the toxicities caused by engineered T cells and novel strategies to overcome them.


2016 ◽  
Vol 16 (9) ◽  
pp. 566-581 ◽  
Author(s):  
Andrew D. Fesnak ◽  
Carl H. June ◽  
Bruce L. Levine

2017 ◽  
Vol 10 (1) ◽  
Author(s):  
Bea Co

Contrary to conventional cancer therapies, immunotherapy manipulates an individual’s body cells to fight cancer, enhancing the active and dynamic immune interactions between the tumour and host. Cancer immunotherapy provides evidence of success through a variety of treatment approaches. Utilizing T-cells and antibodies, immunotherapy strategies such as T-cell engaging bodies, checkpoint inhibitors and engineered T-cells have significantly increased the chance of survival for many cancer patients. The combinations of these immunotherapies have also granted greater success in the elimination of tumour cells. Immunotherapy breakthroughs have the potential to have a lasting impact on cancer treatment. This literature review sheds light on the importance in further research for cancer immunotherapy and a glimpse at all of its powerful results. Contrairement aux méthodes conventionnelles de traitement anti-cancereux, l’immunothérapie manipule les cellules somatiques d’un patient pour battre contre le cancer, améliorant les interactions immunitaires actives et dynamiques entre la tumeur et l’hôte. Par une variété de méthodes de traitement, il y a une abondance de preuve qui montre le succès exceptionnel dans l’utilisation de l’immunothérapie contre le cancer. Les stratégies immunothérapeutiques, par exemple l’utilisation des anticorps bispécifiques qui engagent les cellules T, des inhibiteurs de checkpoint et les cellules T ingénierées, ont augmenté considérablement la chance de survie pour beaucoup de patients frappés par le cancer. Les combinaisons de ces immunothérapies ont aussi permis des grands succès avec l’élimination des cellules cancéreux. L’immunothérapie a mené à des nombreuses percées qui vont avoir un impact durable sur le traitement de cancer. Elle fournit continuellement des nouvelles découvertes qui ont déjà commencées de révolutionner les thérapies de cancer. Cette revue littéraire éclaircit l’importance de la continuation des recherches concernant l’immunothérapie pout le cancer et donne aussi un aperçu de tous ses résultats puissants. 


Sign in / Sign up

Export Citation Format

Share Document